Alkermes plc. (ALKS) stock

ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value

$46.98−0.91 (-1.90%)

Close on Nov 12, 2026Market cap $7.88BP/E 123.6Yield –

Alkermes price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Alkermes's price to sales ratio was 4.8× on Nov 11, 2026, against 3.2× a year earlier. Over the last 5 years it ranged from 2.3× to 5.6×, with a median of 3.4×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	4.8×	+1.8
2025	Dec 31, 2025	3.0×	−0.1
2024	Dec 31, 2024	3.1×	+0.2
2023	Dec 29, 2023	2.9×	−0.9
2022	Dec 30, 2022	3.8×	+0.5
2021	Dec 31, 2021	3.3×	+0.6
2020	Dec 31, 2020	2.7×	−0.3
2019	Dec 31, 2019	3.0×	−1.4
2018	Dec 31, 2018	4.4×	−5.6
2017	Dec 29, 2017	10.0×	−2.1
2016	Dec 30, 2016	12.1×	−8.5
2015	Dec 31, 2015	20.7×	+7.1
2014	Dec 31, 2014	13.6×	+4.2
2013	Dec 31, 2013	9.4×	+4.9
2012	Dec 31, 2012	4.6×	−5.2
2011	Dec 30, 2011	9.8×	+3.3
2010	Dec 31, 2010	6.5×	–